International Journal of Life science and Pharma Reviews (IJLPR)  
  Aim and Scope - To publish peer reviewed review articles in rapidly developing field of Pharma and life sciences  
Life Science
Volume 12 Issue 3, May 2022    Pages:33-39
Treating Psoriatic Arthritis by TNF –Α Inhibitors: A Case Study

Zhuravleva Nadezhda Vladimirovna, Sharapova Olga Viktorovna, Gerasimova Liudmila Ivanovna , Diomidova Valentina Nikolaevna, Smirnova Tatiana Lvovna, Ukhterova Nadezhda Dmitrievna, Karzakova Luiza Mik
[View PDF]
Psoriatic arthritis (PsA) is a heterogeneous seronegative chronic inflammatory spondyloarthritis associated with psoriasis. Doctors consider PsA hard in complex treatment. The purpose of the study is to perform the analysis of clinical data and to identify the features of psoriatic arthriti's and selecting drug therapy.The patient's condition clinical assessment has carried out by using clinical, laboratory and instrumental methods with calculating the Psoriasis Area and Severity Index (PASI), the CASPAR diagnostic criteria and the genetically engineered biological drugs treatment.In the clinical case we studied, a patient with a history of psoriasis has first diagnosed with widespread skin psoriasis at the age of 12, when he carried out medicamentous therapy combined with PUVA. Despite the use of glucocorticosteroids, no complete regression of psoriasis has observed, and the PASI score was 35.3-36.3 points. At the age of 30, the patient developed lower back pains, enthesitis, the PASI score was of 37.1 points. Nonsteroidal anti-inflammatory drugs were added to the treatment. At the age of 42, he was diagnosed with psoriatic arthritis, activity III, stage II, dactylitis, enthesites, the PASI index was 31.3 points; right-sided active sacroiliitis - radiologically stage 1 (BASDAI 4.2 points), FCS 2-3". According to the CASPAR criteria, 4 points were obtained at the time of the disease diagnosis (current psoriasis - 2 points, familial psoriasis - 1 point, negative rheumatoid factor - 1 point). In 2016, at the age of 48, Adalimumab therapy has started according to the scheme in combination with Methotrexate, as a result it was possible to achieve psoriatic arthritis remission and the skin rashes' regressed and 0 PASI score.The psoriatic arthritis therapy with the use of Adalimumab - TNF-α - inhibitor contributed to the disease's long-term stable remission and completed the psoriatic skin rashes regression.
Keywords: psoriatic arthritis, psoriasis, genetically engineered biological drugs (GEBD), Psoriasis Area and Severity Index (PASI), recommendations of the European Anti-Rheumatic League (EULAR) and the American
Full HTML:

Gossec L., Baraliakos X., Kerschbaumer A., de Wit M., McInnes I., Dougados M. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the rheumatic diseases. 2020.79(6):700-712. doi: 10.1136/annrheumdis-2020-217159.

2.       Kaine J, Song X, Kim G, Hur P., Palmer J.B. Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data. Journal of managet care and specialty pharmacy. 2019; 25(1): 122–132. doi: 10.18553/jmcp.2018.17421.

3.       Iragorri N., Hazlewood G., Manns B., Danthurebandara V., Spackman E. Psoriatic arthritis screening: a systematic review and meta-analysis. Rheumatology (Oxford). 2019; 58(4):692-707. doi: 10.1093/rheumatology/key314.

4.       Tom B.D., Chandran V., Farewell V.T., Rosen C.F., Gladman D.D. Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). The journal of rheumatology.2015; 42(5): 841–846. doi: 10.3899/jrheum.140857.

5.       Burlando M, Cozzani E, Schiavetti I, Cicchelli S, Repetto M, Rossotto G, Scaparro E, Parodi A. The STRIPP questionnaire (Screening Tool for Rheumatologic Investigation in Psoriatic Patients) as a new tool for the diagnosis of early psoriatic arthritis. Giornale italiano di  dermatologia e venereologia. 2020; 155(3):294-298. doi: 10.23736/S0392-0488.17.05745-5.

6.       Tom S., Zhong Y., Cook R., Aydin S.Z., Kaeley G., Eder L. Development of a Preliminary Ultrasonographic Enthesitis Score in Psoriatic Arthritis - GRAPPA Ultrasound Working Group. The Journal of rheumatology. 2019; 46(4):384-390. doi: 10.3899/jrheum.171465.

7.       Gossec L., de Wit M., Kiltz U., Braun J., Kalyoncu U., Scrivo R. et al.; EULAR PsAID Taskforce. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the rheumatic diseases. 2014; 73(6):1012-1019. doi: 10.1136/annrheumdis-2014-205207

8.       Haroon M., Winchester R., Giles J.T., Heffernan E., FitzGerald O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Annals of the rheumatic diseases. 2016; 75(1):155-162. doi: 10.1136/annrheumdis-2014-205461.

9.       Stuart P.E., Nair R.P., Tsoi L.C., Tejasvi T., Das S., Kang H.M. et al. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. American journal of human genetic. 2015; 97(6):816-836. doi: 10.1016/j.ajhg.2015.10.019.

10.     Gossec L., Smolen J.S., Ramiro S., de Wit M., Cutolo M., Dougados M. et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the rheumatic diseases. 2016; 75(3):499-510. doi: 10.1136/annrheumdis-2015-208337.

11.     Coates L.C., Kavanaugh A., Mease P.J., Soriano E.R., Laura Acosta-Felquer M., Armstrong A.W. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.  Arthritis and rheumatology. 2016; 68(5):1060-1071. doi: 10.1002/art.39573.

12.     Addimanda O., Possemato N., Caruso A., Pipitone N., Salvarani C. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.The journal of rheumatology Supplement. 2015; 93:73-78. doi: 10.3899/jrheum.150642.

13.     Gorlier C., Orbai A.M., Puyraimond-Zemmour D., Coates L.C., Kiltz U., Leung Y.Y. et al. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.  Annals of the rheumatic diseases. 2019; 78(2):201-208. doi: 10.1136/annrheumdis-2018-214140.

14.     Kavanaugh A., Mease P.J., Gomez-Reino J.J., Adebajo A.O., Wollenhaupt J., Gladman D.D. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. 2014; 73(6):1020-1026. doi: 10.1136/annrheumdis-2013-205056.

15.     Yiu Z.Z, Warren R.B. Ustekinumab for the treatment of psoriasis: an evidence update. Seminars in cutaneous medicine and surgery. 2018;37(3):143-147. doi: 10.12788/j.sder.2018.040.

16.     Katsevman G.A., Mariscal G., Barrios C., Domenech-Fernández P., Ziembinski C., Bhatia S. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis. Monoclonal antibodies in Immunodiagnosis and immunotherapy. 2020;39(5):160-166. doi: 10.1089/mab.2020.0022.l

17.     Yaghoobi R., Soghrati M., Pazyar N., Parvin N. Investigating the effect of 1% curcumin gel and placebo on patients with plaque psoriasis. International Journal of Life science and Pharma Research (IJLPR). 2018. 8(4):48-57doi:

© 2010-2015 IJLPR rights reserved. Specialized onine journals by ubijournal. Website by Ubitech Solutions